Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
October 18 2022 - 4:00PM
Roivant Sciences (Nasdaq: ROIV) today announced that it will host a
live conference call and webcast at 8:00 a.m. EST on Monday,
November 14, 2022 to report its financial results for the second
quarter ended September 30, 2022 and provide a corporate
update.
To access the conference call by phone, please
register online using this registration link. A webcast of the call
will also be available under “Events & Presentations” in the
Investors section of the Roivant website at
https://investor.roivant.com/news-events/events. The archived
webcast will be available on Roivant’s website after the conference
call.
In addition, Roivant will participate in
three upcoming investor conferences:
- Credit Suisse 31st Annual Healthcare Conference in Rancho Palos
Verdes, CA from November 7-10. CFO Richard Pulik will present at
7:25 p.m. EST (4:25 p.m. PST) on Tuesday, November 8.
- Jefferies 2022 London Healthcare Conference in London from
November 15-17. CEO Matt Gline will present at 10:15 a.m. EST (3:15
p.m. GMT) on Tuesday, November 15.
- Evercore ISI HealthCONx Conference, held virtually from
November 29-December 1. CEO Matt Gline will present at 4:20 p.m.
EST on Wednesday, November 30.
A live webcast of each presentation will be
available under “Events & Presentations” on the Investors
section of the Roivant website
at https://investor.roivant.com/news-events/events and an archived
recording will be available after the presentation.
About Roivant
Sciences Roivant's mission is to improve the delivery
of healthcare to patients by treating every inefficiency as an
opportunity. Roivant develops transformative medicines faster by
building technologies and developing talent in creative ways,
leveraging the Roivant platform to launch 'Vants' – nimble and
focused biopharmaceutical and health technology companies. For more
information, please visit www.roivant.com.
Roivant Sciences Forward-Looking
Statements
This press release contains forward-looking
statements. Statements in this press release may include statements
that are not historical facts and are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act"), and Section 21E of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), which are
usually identified by the use of words such as "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intends,"
"may," "might," "plan," "possible," "potential," "predict,"
"project," "should," "would" and variations of such words or
similar expressions. The words may identify forward-looking
statements, but the absence of these words does not mean that a
statement is not forward-looking. We intend these forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the
Securities Act and Section 21E of the Exchange Act.
Contacts
Investors
Roivant Investor Relations
ir@roivant.com
Media
Paul Davis
Roivant Sciences
paul.davis@roivant.com
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Dec 2024 to Jan 2025
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Jan 2024 to Jan 2025